All In Biotech

Drug Trial Radar · NCT07764705

A Mass Balance Study of [14C]HS-10504

A Mass Balance Study of [14C]HS-10504 in Healthy Adult Male Chinese Participants

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Sep 30, 2026

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-site, non randomized, open-label study to assess the absorption, metabolism, and excretion profile of \[14C\] HS-10504 in healthy adult male subjects.

Conditions

  • Healthy Subjects

Interventions

  • [¹⁴C]HS-10504Drug

    \[¹⁴C\]HS-10504: Participants will receive a single oral administration of approximately 400 mg/200 μCi \[¹⁴C\]HS-10504 under fasting conditions on day 1 morning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total radiorecovery and cumulative radiorecovery in urine and feces per time interval.Time frame: All excreted urine and feces samples from pre-dose to Day 21(504 hours) or meet the protocol-specified criteria for termination of sample collection.
  2. Percentage of major metabolites in human plasma, urine, and feces.Time frame: Plasma, urine and feces samples from pre-dose to Day 21(504 hours) or meet the protocol-specified criteria for termination of sample collection.
  3. The percentage of plasma total radioactivity exposure accounted for by the parent compound and its metabolites (%AUC).Time frame: Plasma samples from pre-dose to Day 21(504 hours) or meet the protocol-specified criteria for termination of sample collection.
  4. The percentage of the administered dose recovered as parent drug and metabolites in urine and fecesTime frame: Urine and feces samples from pre-dose to Day 21(504 hours) or meet the protocol-specified criteria for termination of sample collection.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.